Liu Yang, Yin Yanying, Lu Qiao-Li, Dan Ying, Xu Mei-Song, Song Ge, Li Chen
Department of Neurology, Fifth Central Hospital of Tianjin, Binhai Hospital of Peking University, Tianjin, 300450.
Department of Clinical Medicine, Xinxiang Medical University, Henan, 453003, China.
Medicine (Baltimore). 2019 Feb;98(6):e13685. doi: 10.1097/MD.0000000000013685.
Previous clinical trials have reported that vinpocetine can be used for the treatment of cognitive dysfunction. However, its efficacy is still inconclusive. In this systematic review study, we aim to assess its efficacy and safety for the treatment of poststroke cognitive dysfunction (PSCD).
We will search the following electronic databases from the inception to the present to evaluate the efficacy and safety of vinpocetine for patients with PSCD. These databases include CENTRAL, EMBASE, MEDILINE, CINAHL, AMED, and four Chinese databases. All randomized controlled trials (RCTs) of vinpocetine for PSCD will be considered for inclusion without the language restrictions. The methodological quality of all included RCTs will be evaluated by the Cochrane risk of bias tool. The 95% confidence intervals will be utilized to calculate the continuous data, the mean difference or standard mean difference, and dichotomous data with risk ratio.
The results of this review will be disseminated through peer-reviewed journals. Its results may provide important evidence for the clinical practice, as well as the future studies. It does not require ethical approval, because this systematic review will not involve the individual data.
PROSPERO CRD42018115224.
既往临床试验报告长春西汀可用于治疗认知功能障碍。然而，其疗效仍不明确。在这项系统评价研究中，我们旨在评估其治疗卒中后认知功能障碍（PSCD）的疗效和安全性。
我们将检索以下电子数据库，从建库至当前，以评估长春西汀治疗PSCD患者的疗效和安全性。这些数据库包括Cochrane系统评价数据库、Embase、医学期刊数据库、护理学与健康领域数据库、澳大利亚医学索引数据库以及四个中文数据库。所有长春西汀治疗PSCD的随机对照试验（RCT）将被纳入，无语言限制。所有纳入的RCT的方法学质量将通过Cochrane偏倚风险工具进行评估。95%置信区间将用于计算连续数据、平均差或标准化平均差以及具有风险比的二分数据。
本评价结果将通过同行评审期刊进行传播。其结果可能为临床实践以及未来研究提供重要证据。不需要伦理批准，因为本系统评价不涉及个体数据。
国际前瞻性系统评价注册库CRD42018115224。
